GeoVax (GOVX) Reports 2025 Year-End Financial Results and Provides Business Update
LIVE QUOTE
Pivotal Phase 3 Trial for GEO-MVA (Mpox/Smallpox Vaccine)
Scheduled to Initiate During the Second Half of This Year
ATLANTA, GA - April 15, 2026 (NEWMEDIAWIRE)...
Report: AI Powered Review on GeoVax (GOVX) $1.15
In our view, a research report is designed to gather information on publicly traded companies from press releases, management presentations (including power points), SEC...
Adding Cabaletta (CABA) $3.07, GeoVax (GOVX) $1.14, PolyPid (PYPD) $4.68 and Replimune (REPL) $2.17...
Biotech 12 Pack Watch List to be Released.
Biotech Stock Review is Back! Timing Feels Perfect. 4 Companies Added to Watch List.
In 2020, we Released...
Replimune (REPL). $269 Million in Cash and a $178 Million Market Cap. What are...
Adding Replimune to 2026 Watch List @ $2.17
Wife: "Honey, I'm going to the mall, do we have money in the checking?" CEO "Yes, but...
Latest article
Adding BCM Resources Corporation (B.V) $0.27, Up 42%, to Watch List.
'Elephant Hunter' Dr. Sergei Diakov is Expanding Drill Footprint, to Outline a Potentially Massive Copper-Gold System Beneath the Surface.
Led by legendary geologist Dr. Sergei...
New Report on Sekur Private Data (SWISF). Palantir’s Open Secure AI.
Palantir CEO Alex Karp discusses open-weight artificial intelligence models, how he believes the technology should be regulated and why the U.S. should avoid Europe’s...
Replimune (REPL) Jumps 100%.
A Nifty $415 Million Gain (in an hour) for Shareholders.
Not out of the woods yet..
Short and to the point: We listened to whole meeting...
